CompletedHealthcare5 May 2026

Merck to acquire Terns Pharmaceuticals, Inc.

Verified deal facts, source-backed narrative, and the Exit Mode founder lens for SME readers preparing to sell.

Deal facts

Buyer
Merck
Target
Terns Pharmaceuticals, Inc.
Deal value
Not disclosed
Announced
5 May 2026
Status
Completed
Sector
Healthcare
Country
United States
Consideration
cash
What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update
  1. CompletedClosed

    Merck completes acquisition of Terns Pharmaceuticals, Inc.

    Introductory Note As previously disclosed in the Current Report on Form 8-K filed with the Securities and Exchange Commission (the “ SEC ”) by Terns Pharmaceuticals, Inc., a Delaware corporation (“ Terns ”), on March 25, 2026, Terns entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), dated as of March 24, 2026, with Merck Sharp & Dohme LLC, a New Jersey limited liability compa

    Source

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

Similar deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

Buyer history

Merck

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive